

---

# Symprove published research summary

For healthcare professionals only

---

April 2022

Information brought to you by **SYMPROVE™**

# Contents

## Clinical (in vivo) 3

---

### Irritable bowel syndrome 3

- Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome - a 12 week double-blind study (2014)
- A multi-strain water-based probiotic supplement in the management of irritable bowel syndrome or irritable bowel syndrome-like symptoms and quality of life: A real-world evidence study conducted in the United Kingdom (2021)

### Diverticular disease 4

- A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease (2017)

### Inflammatory bowel disease 4

- A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease (2019)

### Oncology 5

- Mucositis reduction with probiotics in children with cancer: a randomised controlled feasibility study (2021)

## Mechanistic (in vitro) 6

---

### Immunomodulatory effects 6

- A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro (2019)

### Anti-pathogenic effects 6

- Use of a water-based probiotic to treat common gut pathogens (2019)
- In vitro inhibition of *Clostridium difficile* by commercial probiotics: A microcalorimetric study (2017)

### Viability 7

- Comparative survival of commercial probiotic formulations: tests in biorelevant gastric fluids and real-time measurements using microcalorimetry (2015)

### Parkinson's disease (SHIME®) 7

- Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease (2021)

### Ulcerative colitis (SHIME®) 8

- A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis (2020)

## Clinical (in vivo)

### Irritable bowel syndrome

#### [Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome - a 12 week double-blind study](#)

Sisson G, et al. *Aliment Pharmacol Ther* 2014;40(1):51–62.

**Background:** The importance of interactions between the host and gut microbiota in the pathogenesis of irritable bowel syndrome (IBS) is becoming increasingly apparent. Probiotics offer a potential new treatment for IBS, but current results are conflicting, largely as a result of poorly designed trials and nonstandardisation of outcome measures. **Aim:** To assess the efficacy of a liquid, multi-strain probiotic (Symprove) in IBS. **Methods:** A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS. Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/kg/day). The primary efficacy measure was the difference in change in the IBS symptom severity score (IBS-SSS) between probiotic vs. placebo at week 12. Secondary outcome measures included change in the IBS quality of life (IBS-QOL) score and change in the IBS-SSS symptom component scores. **Results:** A total of 186 patients were randomised and 152 patients completed the study. The mean change in IBS-SSS was -63.3 probiotic vs. -28.3 placebo. The mean difference in the IBS-SSS was statistically significant [-35.0 (95% CI; -62.03, -7.87); P = 0.01]. There was no significant improvement in the IBS-QOL. No serious adverse events were reported. **Conclusions:** The multi-strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients with IBS, and was well tolerated. These results suggest this probiotic confers benefit in IBS and deserves further investigation.

#### [A multi-strain water-based probiotic supplement in the management of irritable bowel syndrome or irritable bowel syndrome-like symptoms and quality of life: A real-world evidence study conducted in the United Kingdom](#)

Rudland S, et al. *Journal of Primary Care and General Practice* 2021;4(4).

**Background:** Irritable bowel syndrome (IBS) is a common and burdensome functional gastrointestinal disorder of unknown etiology. Due to its complex and multifactorial nature, the delivery of effective management approaches is challenging, with modestly effective therapies and limited efficacy for many conventional drug treatments. To date, some probiotics have shown efficacy in IBS management in randomised clinical trials. The stringent inclusion criteria may not, however, be representative of the wider clinical population. The present study aimed to evaluate the effect of a multi-strain water-based probiotic (Symprove) on participant-reported change in IBS or IBS-like symptoms, and quality of life in a real-life situation. **Methods:** From 6th February to 31st March 2020, real world evidence data were collected from a total of 2301 individuals who retrospectively completed an online questionnaire, of which 1246 (54%) were trialling for IBS or IBS-like symptoms (medically- or self-diagnosed). P values were calculated using proportions Z tests and Mann-Whitney U tests (non-parametric equivalent). Differences are stated as statistically significant where  $P \leq .05$ . **Results:** Of the 1246, 58% (n=717) entered the medically-diagnosed pathway and 40% (n=501) entered the self-diagnosed pathway, 2% (n=28) were omitted from the final analysis. Of the final 1218, over 90% of participants in both IBS cohorts reported improvements ('completely resolved' or 'some positive difference') in IBS or IBS-like symptoms after 4 or more weeks of Symprove, including abdominal pain ( $p < 0.001$ ) bloating ( $p < 0.001$ ), urgency ( $p < 0.001$ ) and bowel habit satisfaction ( $p < 0.001$ ), in addition to quality of life ( $p < 0.001$ ). **Conclusions:** Trialling Symprove for 4 or more weeks was associated with improvements in IBS or IBS-like symptoms, in addition to quality of life. These results support the effectiveness of Symprove in patients with IBS or IBS-like symptoms and may be considered a potentially useful adjunct for patients in primary and secondary care.

## Diverticular disease

### [A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease](#)

Kvasnovsky CL, et al. *Inflammopharmacology* 2017; doi: 10.1007/s10787-017-0363-y.

**Background:** Diverticular disease is a significant burden on healthcare systems that is managed, surgically or medically, mainly as an emergency or acute condition. There are no standardized treatment recommendations for symptomatic uncomplicated disease. We hypothesized that a probiotic would reduce abdominal pain in such patients. **Methods:** We conducted a single-center, double-blind, placebo-controlled trial of probiotic treatment (Symprove) in adult patients with moderate-to-severe chronic, non-acute symptomatic diverticular disease. 143 patients were randomized to receive 1 mL/kg/day of probiotic liquid (N = 72) or placebo (N = 71) daily for 3 months. The primary endpoint was abdominal pain severity. Secondary endpoints consisted of the change in the frequency of eight abdominal symptoms and the level of intestinal inflammation (fecal calprotectin). **Results:** 120 patients completed the trial. Abdominal pain score, the primary end point, decreased in both groups, but no significant difference between the groups was found (P = 0.11). In relation to placebo, the probiotic significantly decreased the frequency of four of the eight secondary endpoints: constipation, diarrhea, mucorrhea, and back pain (P < 0.04). No significant differences were found in frequency of abdominal pain, PR bleeding, dysuria, and bloating. **Conclusions:** Multi-strain liquid probiotic did not improve abdominal pain scores significantly, but significantly improved the frequency of four other symptoms associated with chronic, non-acute symptomatic diverticular disease.

## Inflammatory bowel disease

### [A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease](#)

Bjarnason I, et al. *Inflammopharmacology* 2019;27(3):465–473.

**Background:** There is considerable interest in the possible importance of the gut microflora in the pathophysiology of the inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD). Probiotics offer a potential adjuvant treatment in these patients by modifying the intestinal milieu, but reports of their efficacy are conflicting. **Aims:** To assess the efficacy of a multi-strain probiotic (Symprove™, Symprove Ltd, Farnham, United Kingdom) in quality of life issues and intestinal inflammation in patients with asymptomatic UC and CD. **Methods:** A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with asymptomatic IBD. Patients received 4 weeks of treatment with the probiotic or placebo (1 ml/kg/day). The primary efficacy measure was the difference in change in the IBD Quality of Life Questionnaire results (QOL) between probiotic vs. placebo at week 4. Secondary outcome measures included analyses of the change in laboratory findings, including faecal calprotectin (FCAL). **Results:** Over 500 patients were recruited to the study and 81 and 61 patients with UC and CD, respectively were randomised and completed the study. There were no significant differences in IBD-QOL scores between placebo and the probiotic groups. Similarly, there were no significant changes observed in the laboratory data. However, the differences in FCAL between patients with UC before and after probiotics versus placebo approached statistical significance with a p value of 0.076. Post-hoc analyses showed that the FCAL levels were significantly (p < 0.015) reduced in the UC patients receiving the probiotic as opposed to placebo. No significant changes were seen in CD. No serious adverse events were observed. **Conclusions:** This multi-strain probiotic is associated with decreased intestinal inflammation in patients with UC, but not in CD and is well tolerated. Further research is required to see if the probiotic reduces the incidence of clinical relapses in asymptomatic IBD patients.

## Oncology

### [Mucositis reduction with probiotics in children with cancer: a randomised controlled feasibility study](#)

Hassan H, et al. Arch Dis Child 2022;107(3):259–64.

**Background:** A recent systematic review and meta-analysis identified a paucity of randomised-controlled trials (RCTs) investigating the use of probiotics to reduce or prevent mucositis and infection in children with cancer. **Objective:** This study evaluated the feasibility of undertaking an RCT and investigated the efficacy of probiotics for reducing or preventing mucositis and infection in children with cancers. **Setting:** The Paediatric Oncology and Haematology department at Leeds Teaching Hospital, UK. **Patients:** Children aged 1 year or older, receiving chemotherapies likely to cause mucositis. **Interventions:** Participants were randomised to receive the probiotic or placebo on day 1-14 of a chemotherapy cycle. Participants were also required to complete a patient diary for 21 days. **Main outcome measures:** To assess whether it is feasible to recruit children diagnosed with cancer who are at risk of developing mucositis to an adequately powered RCT. **Results:** Between May and November 2019, 34 out of 39 eligible participants were approached. Ten patients were recruited (4 probiotic and 6 placebo) of which 2 participants withdrew. Seven participants partially completed the diary but only two participants completed 80% or more. Eligible participants appeared to prefer giving informal verbal feedback when in direct contact with research and healthcare professionals. **Conclusion:** This study demonstrated that recruitment needs to be improved prior to undertaking an adequately powered RCT.

## Mechanistic (in vitro)

### Immunomodulatory effects

#### [A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro](#)

Moens F, et al. Int J Pharm 2019;555:1–10.

Poorly formulated probiotic supplements intended for oral administration often fail to protect bacteria from the challenges of human digestion, meaning bacteria do not reach the small intestine in a viable state. As a result, the ability of probiotics to influence the human gut microbiota has not been proven. Here we show how (i) considered formulation of an aqueous probiotic suspension can facilitate delivery of viable probiotic bacteria to the gut and (ii) quantitate the effect of colonisation and proliferation of specific probiotic species on the human gut microbiota, using an in-vitro gut model. Our data revealed immediate colonisation and growth of three probiotic species in the luminal and mucosal compartments of the proximal and distal colon, and growth of a fourth species in the luminal proximal colon, leading to higher proximal and distal colonic lactate concentrations. The lactate stimulated growth of lactate-consuming bacteria, altering the bacterial diversity of the microbiota and resulting in increased short-chain fatty acid production, especially butyrate. Additionally, an immunomodulatory effect of the probiotics was seen; production of anti-inflammatory cytokines (IL-6 and IL-10) was increased and production of inflammatory chemokines (MCP-1, CXCL 10 and IL-8.) was reduced. The results indicate that the probiotic species alone do not result in a clinical effect; rather, they facilitate modulation of the gut microbiota composition and metabolic activity thereby influencing the immune response.

### Anti-pathogenic effects

#### [Use of a water-based probiotic to treat common gut pathogens](#)

Dodoo CC, et al. Int J Pharm 2019;556:136–141.

This work reports the anti-pathogenic effect of a commercially available water-based probiotic suspension, Symprove™, against three commonly encountered infectious organisms; Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA) and Shigella sonnei. An isothermal calorimetric assay was used to monitor growth of the species individually and in binary combinations, while colony plate counting was used to enumerate viable cell numbers. It was observed that all pathogenic species were faster growing than the probiotic bacteria in Symprove™ after inoculation into growth medium yet in all instances bacterial enumeration at the end of the experiments revealed a significant reduction in the pathogen population compared with the controls. A control population between 10<sup>8</sup> and 10<sup>9</sup> CFU/ml was obtained for E. coli and S. sonnei whilst approximately 10<sup>6</sup> CFU/ml was obtained for MRSA. Upon co-incubation for 48 h, no viable counts were obtained for E. coli; a 4-log reduction was obtained for S. sonnei whilst MRSA numbers were down to less than 10 cells/ml. The results show that Symprove™ has antipathogenic activity against E. coli, S. sonnei and MRSA.

#### [In vitro inhibition of Clostridium difficile by commercial probiotics: A microcalorimetric study](#)

Fredua-Agyeman M, et al. Int J Pharm 2017;517(1–2):96–103.

The aim of the study was to investigate the influence of some commercial probiotics on the growth of Clostridium difficile using isothermal microcalorimetry, a technique which can monitor the real time growth of bacteria. Commercial probiotic strains and products, Lactobacillus acidophilus LA-5®, Bifidobacterium lactis BB-12®, Probio 7® and Symprove™ were co-cultured with C. difficile in Brain Heart Infusion (BHI) broth supplemented with 0.1% (w/v) L-cysteine hydrochloride and 0.1% (w/v) sodium taurocholate and monitored in the microcalorimeter. Pseudomonas aeruginosa NCIMB 8628 was also co-cultured with C. difficile and studied. The results indicated inhibition of C. difficile by the probiotics. The inhibition of C. difficile was shown to be pH-dependent using neutralized and unmodified cell free supernatant (CFS) produced by the probiotic strains. However, concentrated CFS of the probiotics also inhibited the intestinal pathogen in a non pH-dependent manner, likely due to specific antimicrobial substances produced. The results also indicated that C. difficile growth was greatly influenced by the presence of sodium taurocholate and by the pH of the medium. A medium pH of between 6.45 and 6.9 demonstrated maximum growth of the organism in the microcalorimeter.

## Viability

### [Comparative survival of commercial probiotic formulations: tests in biorelevant gastric fluids and real-time measurements using microcalorimetry](#)

Fredua-Agymean M, et al. *Benef Microbes* 2015;6(1):141–51.

The large number of probiotic products now available makes the decision about which product to choose difficult both for the consumer and for the specialist providing dietary/nutritional advice. Data on the viability of the bacteria in these products, in an in vivo situation, are therefore important. This study was designed to explore the comparative health and survival of probiotic species in various commercial formulations, using more realistic test systems. This might allow further understanding of factors that must be controlled to optimise the delivery of live healthy bacteria to the lower gut. A total of eight commercially available probiotic preparations were selected for enumeration tests and in vitro gastric tolerance tests. Tolerance assays were conducted in porcine gastric fluid (PGF) fed and fasted state (pH 3.4±0.04), simulated gastric fluid (SGF, pH adjusted to 1.2 and 3.4) and fasted state simulated gastric fluid (FaSSGF, pH adjusted to 1.6 and 3.4). Isothermal microcalorimetry was also used to measure real-time growth of probiotics after exposure to simulated gastric fluid. Results from the enumeration tests indicated that recovery of viable organisms per dose is the same as or better than the stated label claims for liquid-based formulations, but lower than the stated claim for freeze-dried products. Results from the in vitro tolerance tests overall suggest that the PGF provided a harsher environment than the simulated systems at similar pH. In general, liquid-based products tested tended to give superior results in terms of survival compared with the freeze-dried products tested. Results from tests in the fed state in PGF suggested that food greatly affects viability. Microcalorimetric data showed that for some products probiotic species were able to grow following exposure to gastric fluid, suggesting that viable bacteria reach the gut in vivo.

## Parkinson's Disease (SHIME®)

### [Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease](#)

Ghyselinck J, et al. *Int J Pharm X* 2021;3:100087.

We report here the potential role of a 4-strain probiotic suspension for use with patients with Parkinson's disease (PD). Stool samples from a group of three patients with diagnosed PD were used to create microbiotas in an in-vitro gut model. The effects of dosing with an oral probiotic suspension (Symprove) on bacterial composition and metabolic activity in the microbiotas was evaluated over 48 h and compared with healthy controls. Additionally, the effect of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. In general, the relative proportions of the main bacterial phyla in the microbiotas of PD patients differed from those of healthy subjects, with levels of Firmicutes raised and levels of Bacteroidetes reduced. Dosing with probiotic resulted in a change in bacterial composition in the microbiotas over a 48 h period. Several other indicators of gut health changed upon dosing with the probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased and levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased. Tight junction integrity was seen to improve with probiotic dosing and wound healing was seen to occur faster than a control. The data suggest that if development and/or progression of PD is influenced by gut microbiota dysbiosis then supplementation of the diet with a properly formulated probiotic may be a useful adjunct to standard treatment in clinic.

## Ulcerative colitis (SHIME®)

### [A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis](#)

Ghyselinck J, et al. Int J Pharm 2020;587:119648.

Symprove, a multi-strain probiotic, has been shown to exert a mild anti-inflammatory effect in patients with ulcerative colitis (UC). We examined stool samples from 3 patients with UC in order to create microbiotas in an in-vitro gut model. The effects of Symprove on bacterial diversity and metabolic activity in the microbiotas was evaluated over 48 h. In addition, the influence of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. The relative proportions of the main bacterial phyla in UC patients differed from those of healthy subjects studied previously; levels of Firmicutes were lowered and levels of Bacteroidetes were raised. Addition of Symprove changed the bacterial composition in the microbiotas over a 48 h period. Several other factors generally implicated in good gut health changed after dosing with probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased, levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased, epithelial tight junction integrity improved and wound healing occurred faster than a control. The results imply it is not the simple addition of probiotic bacteria that improves gut health. Rather, the probiotic bacteria generate lactate, which then stimulates growth of commensal gut bacteria, raising SCFA levels (particularly butyrate). The increased butyrate concentration positively influences inflammation response and time of wound healing.

**SYMPROVE™**